Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-uncovers-novel-immune-escape-mechanism-of-cancer-opening-up-new-direction-for-cancer-immunotherapy
https://www.med.cuhk.edu.hk/press-releases/cuhk-uncovers-novel-immune-escape-mechanism-of-cancer-opening-up-new-direction-for-cancer-immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

A recent study by the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) has uncovered how cancer cells defeat the frontline of immunity, thereby promoting tumour progression.  The research team found that cancer cells can suppress innate immunity in the tumour microenvironment through activating a key molecule - Smad3.  This new finding has led to a preclinical study with promising results that opens up an unexplored area of ‘immunotherapy’.  The findings have been published in the leading international scientific journalNature Communications.

 

Cancer has long been the leading cause of death in Hong Kong.  One of the major challenges of antitumour treatment lie in the mutations in cancer cells that facilitate their escape from therapies after a period of time.  In recent years, scientists have started to find hints in the surrounding environment of cancer cells affecting their growth – the tumour microenvironment – for beating cancer.

 

Controlling tumour microenvironment becomes a new strategy of anticancer therapy

The tumour microenvironment describes the non-cancerous cells present in a tumour.  These include immune cells, fibroblasts, cells that comprise blood vessels, as well as substances that support the growth of cancer cells.

 

Transforming growth factor-beta1 (TGF-β1), a multifunctional protein is well-documented as a tumour promoter.  Researchers found that cancer cell-derived TGF-β1 supports growth of cancer cells by suppressing the host innate immunity in the tumour microenvironment.

 

The mechanism behind is that TGF-β1 activates Smad3, a key mediator of the signaling pathway, in order to suppress Natural Killer cell (NK cell) immunity against cancer.  NK cell is an important component of the first line immune defence against cancer. The CUHK team further investigated the underlying mechanism with two syngeneic mice tumour models (with invasive lung carcinoma and melanoma respectively).  Compared to the control group, mice with Smad3-free microenvrionment were protected against tumour growth, invasion, metastasis and death.

 

Prof. Hui Yao LAN, Choh-Ming Li Professor of Biomedical Sciences and Assistant Dean (Research), Faculty of Medicine, CUHK elaborated, ‘We observed a 10-fold increase in NK cell production and enhanced cancer-killing activities in the Smad3-free tumour microenvironment.  This suggests that Smad3 is an important checkpoint for TGF-β mediated immunosuppression in the tumour microenvironment.

 

Smad3 inhibition as a new target for immunotherapy

The CUHK team further proved that Smad3 can directly inhibit the expression of E4BP4 gene, the master transcription factor for NK cell production, thereby suspending NK cell production.  Removal of Smad3 can thus restore the development of NK cells and thereby inhibiting cancer progression.

 

Dr. Patrick Ming Kuen TANG, Research Associate, Department of of Anatomical and Cellular Pathology, Faculty of Medicine, CUHK said, ‘These novel observations have led us to the hypothesis that targeting Smad3 in the tumour microenvironment may awake patients’ NK cell immunity against cancer.’

 

Inspired by these findings, pre-clinical works of Smad3-targeted anticancer therapy has been started by treating two syngeneic mouse tumour models with a Smad3 inhibitor.  Results showed that systemic treatment with Smad3 inhibitor can effectively suppress cancer progression by increasing NK cell production and anticancer activity as well as reducing other cancer-promoting factors in the tumour microenvironment.

 

Prof. Ka Fai TO, Chairman, Department of Anatomical and Cellular Pathology, Faculty of Medicine, CUHK said, ‘NK cell being the main effector cells in innate immunity is the first and powerful immune defence mechanism against cancer.  However, cancer cells manage to suppress NK cells activities in the tumour microenvironment and grow into invasive tumour.  Boosting up NK cells activities is a promising anti-cancer approach, but the success is limited by the lack of understanding how cancer cells suppress NK cells.  This study has identified the key immune regulator and suggested a novel immunotherapeutic strategy to awake our own immunity to fight against cancer.’

 

Professor LAN added, ‘We are trying to apply the concept of Traditional Chinese Medicine “Yin & Yang(陰陽)”.  In this study we discovered that cancer cells can block NK cells production via activating Smad3, resulting in a loss of the bright side “Yang” of our immunity.  The use of an optimal tranditional Chinese medicine formula may help inhibit Smad3 activation and rebalance the “Yin &Yang” in the tumour microenviornment, i.e. the concept of “strengthening the vital but eliminating the pathogen”(扶正抑邪).  This formula may represent a novel, effective and safe anti-cancer treatment.

 

The research team is also working on a new form of Smad3 inhibitor by applying nanotechnology, which may open up a new direction of cancer immunotherapy.

 

The Faculty of Medicine of CUHK uncovers how cancer cells defeat the frontline of immunity, thereby pointing new direction for immunotherapy. From left: Prof. Ka Fai TO, Chairman, Department of Anatomical and Cellular Pathology, Faculty of Medicine, CUHK; Prof. Hui Yao LAN, Choh-Ming Li Professor of Biomedical Sciences and Assistant Dean (Research), Faculty of Medicine, CUHK; Dr. Patrick Ming Kuen TANG, Research Associate, Department of of Anatomical and Cellular Pathology, Faculty of Medicine, CUHK.

The Faculty of Medicine of CUHK uncovers how cancer cells defeat the frontline of immunity, thereby pointing new direction for immunotherapy. From left: Prof. Ka Fai TO, Chairman, Department of Anatomical and Cellular Pathology, Faculty of Medicine, CUHK; Prof. Hui Yao LAN, Choh-Ming Li Professor of Biomedical Sciences and Assistant Dean (Research), Faculty of Medicine, CUHK; Dr. Patrick Ming Kuen TANG, Research Associate, Department of of Anatomical and Cellular Pathology, Faculty of Medicine, CUHK.

Prof. Hui Yao LAN (centre) says the study identifies Smad3 as a key immune regulator, and hence opens up a new direction for immunotherapy.

Prof. Hui Yao LAN (centre) says the study identifies Smad3 as a key immune regulator, and hence opens up a new direction for immunotherapy.

 The target of the new suggested immunotherapy approach is to resume the immunity of NK cells through inhibition of Smad3, thus to kill cancer cells.

The target of the new suggested immunotherapy approach is to resume the immunity of NK cells through inhibition of Smad3, thus to kill cancer cells.

More Press Releases

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK’s Gerald Choa Neuroscience Centre Unveils Mystery of How Brain Learns Motor Skills

CUHK’s Gerald Choa Neuroscience Centre Unveils Mystery of How Brain Learns Motor Skills

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
CUHK Study Discovers Pathway That Links to Cognitive Flexibility Dopamine Dysregulation May Lead to Ability Impairment

CUHK Study Discovers Pathway That Links to Cognitive Flexibility Dopamine Dysregulation May Lead to Ability Impairment

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Study Discovers an Essential Enzyme to Maintain Body Iron Homeostasis Deficiency Could Cause Excessive Iron Retention and Damage Major Organs

CUHK Study Discovers an Essential Enzyme to Maintain Body Iron Homeostasis Deficiency Could Cause Excessive Iron Retention and Damage Major Organs

Research
CUHK School of Biomedical Sciences Strives to Become the World-leading Biomedical Hub

CUHK School of Biomedical Sciences Strives to Become the World-leading Biomedical Hub

Milestone
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Professor Hui Yao LAN’s Research on Chronic Kidney Disease Wins First Prize in Chinese Medical Science and Technology Award

CUHK Professor Hui Yao LAN’s Research on Chronic Kidney Disease Wins First Prize in Chinese Medical Science and Technology Award

Awards and honors
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.